Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AMGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amgen Inc ranked in the 44th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Amgen Inc, consider:
AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 27.38% of tickers in our DCF set.
The weighted average cost of capital for the company is 7. This value is greater than only 13.48% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMGN, try FONR, HNGR, CRL, DGX, and STE.
In this article we will check out the progression of hedge fund sentiment towards Amgen, Inc. (NASDAQ:AMGN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate to discuss Amgen's oncology program, including data being presented on the Company's KRASG12C inhibitor sotorasib.
Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were represented at the meeting.